Vaxxas

About

Vaxxass is a biotechnology company focused on needle-free vaccination technology.

Brisbane,Queensland,Australia
51 - 100
http://www.vaxxas.com

Highlights

Details

Last Funding Type: Series C
Last Funding Money Raised: $34M
Industries: Biotechnology,Health Care,Medical Device
Founded date: Jan 1, 2011
Number Of Employee: 51 - 100
Operating Status: Active
Legal Name: Vaxxas Pty. Ltd
Also Known As: Vaxxas, Inc.

Vaxxass is a biotechnology company that develops a novel needle-free vaccination technology. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain".

Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

7

$61.60M $52M

Vaxxas has raised a total of $61.60M $52M in funding over 2 rounds. Their latest funding was raised on Dec 5, 2022 from a Series C round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 5, 2022	Series C	$34M	2	OneVentures UniQuest,	—	Detail
Sep 20, 2022	Grant	$8.20M	1	Australian Government	—	Detail
Jan 1, 2021	Grant	$4.40M	1	Australian Government	—	Detail
Oct 5, 2020	Grant	$22M	1	Biomedical Advanced Research and Development Authority (BARDA)	—	Detail
Mar 17, 2020	Grant	$5M	1	Bill & Melinda Gates Foundation	—	Detail

Investors

Number of Lead Investors

Number of Investors

8

Vaxxas is funded by 8 investors. OneVentures and UniQuest, are the most recent investors.

Investor Name	Lead Investor	Funding Round
OneVentures	Yes	Series C
UniQuest,	Yes	Series C
Australian Government	Yes	Grant
Biomedical Advanced Research and Development Authority (BARDA)	Yes	Grant
Bill & Melinda Gates Foundation	Yes	Grant
HealthCare Ventures	—	Series B
Brandon Capital Partners	—	Series A
Medical Research Commercialisation Fund (MRCF)	—	Series A